Skip Navigation


Rheumatology Advance Access originally published online on March 9, 2006
Rheumatology 2006 45(7):787-789; doi:10.1093/rheumatology/kel075
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME/CE:
Take the course for this article:
 Rheumatology Second Quarter 2006 Quiz
Right arrow All Versions of this Article:
45/7/787    most recent
kel075v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Saravanan, V.
Right arrow Articles by Kelly, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saravanan, V.
Right arrow Articles by Kelly, C.
Related Collections
Right arrow Rheumatoid Arthritis
Right arrow Rehabilitation
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

EDITORIAL

Drug-related pulmonary problems in patients with rheumatoid arthritis

V. Saravanan and C. Kelly

Department of Medicine and Rheumatology, Queen Elizabeth Hospital, Gateshead, UK

Correspondence to: C. Kelly, Queen Elizabeth Hospital, Sheriff Hill, Gateshead Health NHS Trust, Tyne and Wear NE9 6SX, UK. E-mail: clive.kelly@ghnt.nhs.uk

The first 150 words of the full text of this article appear below.

There has been growing concern lately over the development of serious lung disease in patients with rheumatoid arthritis (RA) receiving certain categories of drug therapy. The Committee on Safety of Medicines [1] and the National Patient Safety Agency [2] have issued new recommendations on monitoring for pulmonary symptoms in patients taking methotrexate. The development of acute pulmonary infiltrates in patients taking leflunomide [3–6] and worsening of pre-existing interstitial fibrosis with the use of some anti-TNF agents, notably infliximab [7], have sparked concerns over the safety of these drugs. However, anxiety about drug-related lung disease is not new to rheumatologists. The literature on disease-modifying anti-rheumatic drugs (DMARDs) is dotted with reports of ‘penicillamine-induced bronchiolitis’, ‘gold lung’ and even sulphasalazine-induced pneumonitis. We have to consider the possibility that pneumonitis occurring de novo or the worsening of pre-existing interstitial fibrosis in RA may be due . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
C. Balakrishnan and B. Dasgupta
Pulmonary adverse events with leflunomide--myth or reality?
Rheumatology, February 1, 2007; 46(2): 372 - 372.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
Y. Yazici and H. Yazici
Comment on 'Drug-related pulmonary problems in patients with rheumatoid arthritis'
Rheumatology, February 1, 2007; 46(2): 371 - 372.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
V. Saravanan and C. A. Kelly
Reply to comment on 'Drug-related pulmonary problems in patients with rheumatoid arthritis' by Yazici and Yazici and 'Pulmonary adverse events with Leflunomide--myth or reality?' by Balakrishnan and Dasgupta
Rheumatology, February 1, 2007; 46(2): 372 - 373.
[Full Text] [PDF]